<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2502">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710550</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002254</org_study_id>
    <nct_id>NCT04710550</nct_id>
  </id_info>
  <brief_title>Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury</brief_title>
  <official_title>Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to obtain an initial assessment of the value of using [18F]3F4AP for&#xD;
      imaging demyelinating diseases such as traumatic brain injury (TBI), neurodegenerative&#xD;
      diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD):&#xD;
&#xD;
        -  Aim 1) Assess the safety of [18F]3F4AP in healthy volunteers and subjects with traumatic&#xD;
           brain injury (TBI) and neurocognitive impaired subjects (AD/MCI). Hypothesis 1:&#xD;
           Administration of [18F]3F4AP will result in no changes in vitals or other adverse&#xD;
           events.&#xD;
&#xD;
        -  Aim 2) Assess the radiation doses to the main organs in healthy volunteers. Hypothesis&#xD;
           2: the radiation doses to each organ will be comparable in all subjects and within the&#xD;
           acceptable limits.&#xD;
&#xD;
        -  Aim 3) Assess the pharmacokinetics of a bolus infusion of [18F]3F4AP in humans including&#xD;
           healthy volunteers and patients. Hypothesis 3: the pharmacokinetics of [18F]3F4AP at the&#xD;
           whole brain level will be similar in controls, TBI and AD/MCI subjects. The kinetics in&#xD;
           demyelinated lesions will be slower than in healthy areas.&#xD;
&#xD;
        -  Aim 4) Correlate MR images with [18F]3F4AP PET images. Hypothesis 4A: all the lesions&#xD;
           seen on the MRI will show increased signal (VT or SUV) on the PET images. Hypothesis 4B:&#xD;
           some of the lesions on the MRI will show increased signal (VT or SUV) on the PET but not&#xD;
           all.&#xD;
&#xD;
        -  Aim 5) Correlate [18F]3F4AP PET signal with neuropsychological testing in people with&#xD;
           TBI and AD/MCI. Hypothesis 5A: increased PET signal (VT or SUV) will correlate with&#xD;
           impaired Mini Mental State Examination (MMSE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>5 years</time_frame>
    <description>Determine number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <condition>Demyelinating Disorder</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Safety/Dosimetry Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD/MCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F18-3F4AP</intervention_name>
    <description>PET Scan</description>
    <arm_group_label>AD/MCI</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Safety/Dosimetry Cohort</arm_group_label>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are 18 years of age and older, except AD subjects who are 60 to 90 years of&#xD;
             age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will not be eligible for inclusion in this study if any of the exclusion&#xD;
             criteria for PET/CT or MRI studies applies. A negative STAT quantitative serum hCG&#xD;
             pregnancy test is required on the day of the PET/CT scan before female subjects of&#xD;
             childbearing potential can participate. Any woman of childbearing potential, who is&#xD;
             seeking to become pregnant, is breastfeeding, or who suspects she may be pregnant will&#xD;
             not be enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges El Fakhri, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass. General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georges El Fakhri, PhD</last_name>
    <phone>617-726-9640</phone>
    <email>ELFAKHRI.GEORGES@MGH.HARVARD.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia-Ann Scotton, BS</last_name>
      <phone>617-643-1967</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>May 4, 2022</last_update_submitted>
  <last_update_submitted_qc>May 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Georges El Fakhri</investigator_full_name>
    <investigator_title>Director, Gordon Center for Medical Imaging</investigator_title>
  </responsible_party>
  <keyword>3F4AP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

